30 closest matches · ranked by relevance
Squamous Non-small Cell Lung Cancer
Primary: Time on Treatment With Afatinib or Chemotherapy During Second Line (2L) Treatment — 7.3; 4.2 months
Squamous Cell Lung Carcinoma
Primary: Objective Response Rate (ORR) — 0 Participants
Metastatic Skin Squamous Cell Carcinoma · Recurrent Skin Squamous Cell Carcinoma
Primary: Overall Response Rate — 3 Participants
Skin Cancer
Primary: Number of Participants With Objective Response (Partial Response, Stable Disease and Progressive Disease) — 14; 4; 19 participants
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Cancer
Primary: Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments. — 15; 14; 12; 13 number of adverse events
Non-Small Cell Lung Cancer
Primary: Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events — 1; 7; 0; 1 Participants
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Neck
Primary: Toxicity — 0; 1; 2 participants
CCND1 Gene Amplification · CCND2 Gene Amplification · CCND3 Gene Amplification
Primary: Objective Response Rate (Confirmed and Unconfirmed, Complete and Partial) — 6 percentage of participants
Lung Cancer · Untreated Stage IV or Recurrent Squamous Cell Lung Cancers
Primary: Overall Response Rate — 18; 1; 5; 12 Participants
Esophageal Squamous Cell Carcinoma
Primary: 1-year Relapse-free Survival Rate — 14.3 months
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
ATM Gene Mutation · ATR Gene Mutation · BARD1 Gene Mutation
Primary: Overall Response Rate Assessed by Response Evaluation Criteria in Solid Tumors 1.1 in HRRD-positive (MDVN) Participants — 4 percentage of participants
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Median Overall Survival — 231 Days
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 2.89; 2.76; 2.37; 1.54 months — p=0.756
Squamous NSCLC
Primary: PFS(Progression Free Survival) — 5.5; 4.9 months
Recurrent Squamous Cell Lung Carcinoma · Stage IV Squamous Cell Lung Carcinoma AJCC v7
Primary: Screen Success Rate — 655 Participants
Recurrent Small Cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of Rovalpituzumab Tesirine — 0.4 mg/kg
Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Rate of Disease Control (Freedom From Disease Progression) — 4 participants
Recurrent Small-cell Lung Cancer (SCLC) · Lung Cancer, Small Cell
Primary: Percentage of Participants With Progression-free Survival (PFS) at 3 Months — 65 percentageof participants — p=0.017
Squamous Cell Carcinoma, Non-Small-Cell Lung
Primary: Kaplan-Meier Estimate of Progression-Free Survival (PFS) From Randomization Into Maintenance — 3.12; 2.60 months — p=0.3486
Squamous Cell Carcinoma of the Head and Neck
Primary: 1-year Local Progression-free Survival (PFS) — 60 percentage of participants
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) by Dichotomized Baseline Plasma Marker Level — 42.86; 47.69…
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Lung Cancer
Primary: Overall Response Rate — 65; 50 percentage of participants
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Recurrent Non-small Cell Lung Cancer
Primary: Objective Response Rate — 0; 0 percentage of responding patients
Squamous Cell Non-small Cell Lung Cancer
Primary: Objective Response Rate (ORR) as Assessed by Independent Radiology Review Committee (IRC) — 14.5 Percentage of Participants
Recurrent Squamous Cell Lung Carcinoma · Stage IV Squamous Cell Lung Carcinoma AJCC v7
Primary: Response Rate in MEDI4736-treated Participants — 16 percentage of participants